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Using serial analysis of gene expression on cultured
human keratinocytes we found high expression levels
of genes putatively involved in host protection and
defense, such as proteinase inhibitors and antimicro-
bial proteins. One of these expressed genes was the
recently discovered cysteine proteinase inhibitor
cystatin M/E that has not been characterized so far
at the protein level with respect to tissue distribution
and additional biologic properties. Here we report
that cystatin M/E has a tissue-speci®c expression pat-
tern in which high expression levels are restricted to
the stratum granulosum of normal human skin, the
stratum granulosum/spinosum of psoriatic skin, and
the secretory coils of eccrine sweat glands. Low
expression levels were found in the nasal cavity. The
presence of cystatin M/E in skin and the lack of
expression in a variety of other tissues was veri®ed
both at the protein level by immunohistochemistry
or western blotting, and at the mRNA level by
reverse transcriptase polymerase chain reaction or
northern blotting. Using biotinylated hexapeptide
probes we found that cystatin M/E is an ef®cient
substrate for tissue type transglutaminase and for
transglutaminases extracted from stratum corneum,
and that it acts as an acyl acceptor but not as an acyl
donor. Western blot analysis showed that recombi-
nant cystatin M/E could be cross-linked to a variety
of proteins extracted from stratum corneum. In vitro,
we found that cystatin M/E expression in cultured
keratinocytes is upregulated at the mRNA and
protein level, upon induction of differentiation. We
demonstrate that cystatin M/E, which has a putative
signal peptide, is indeed a secreted protein and is
found in vitro in culture supernatant and in vivo in
human sweat by enzyme-linked immunosorbent
assay or western blotting. Cystatin M/E showed
moderate inhibition of cathepsin B but was not
active against cathepsin C. We speculate that cystatin
M/E is unlikely to be a physiologically relevant inhi-
bitor of intracellular lysosomal cysteine proteinases
but rather functions as an inhibitor of self and non-
self cysteine proteinases that remain to be identi®ed.
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C
ystatins are natural and speci®c inhibitors of en-
dogenous mammalian lysosomal cysteine proteinases,
such as cathepsins B, L, H, and S (Turk and Bode,
1991; Abrahamson, 1994), and exogenous microbial
cysteine proteinases (Bjorck, 1990). Several studies
have indicated that cystatins provide important regulatory and
protective functions against uncontrolled proteolysis by cysteine
proteinases from host, bacterial, and viral origin (Bobek and Levine,
1992). A disturbed balance between proteinases and their inhibitors
can lead to irreversible damage as in chronic in¯ammatory reactions
(Henskens et al, 1996) and tumor metastasis (Calkins and Sloane,
1995). In addition to their proteinase inhibitory activity, some of
the cystatins (C and S) were shown to have antimicrobial activity
against bacteria (Bjorck et al, 1989; Blankenvoorde et al, 1998) and
viruses (Korant et al, 1986; Bjorck et al, 1990). Cystatins are
members of a superfamily of evolutionary related proteins and can
be divided into three major families (Rawlings and Barrett, 1990):
family 1 cystatins A and B (or stef®ns A and B), family 2 cystatins
(C, D, S, SN, and SA), and the kininogens, which belong to family
3 cystatins. A new member of the human cystatin superfamily,
named cystatin M, was recently identi®ed and characterized
(Sotiropoulou et al, 1997). The gene was identi®ed by differential
display, comparing mRNAs from primary and metastatic breast
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tumor cells, and was found to be downregulated in metastatic cells.
The same cystatin was independently found by expressed sequence
tag sequencing in epithelial-cell-derived cDNA libraries and
reported as cystatin E (Ni et al, 1997). Cystatin M/E is a 14 kDa
protein that shares a 35% homology with the human family 2
cystatins, has similar overall structures, such as signal peptide and
two intrachain disul®de bonds, but possesses the unusual
characteristic of being a glycoprotein. Cystatin M/E proved to be
a potent inhibitor of papain and cathepsin B (Ni et al, 1997;
Sotiropoulou et al, 1997), although speci®c physiologic functions or
target molecules have not been reported so far. Cystatin M/E was
reported to have a broad tissue distribution at the mRNA level,
although the reports of Ni et al and Sotiropoulou et al gave
con¯icting results. No tissue localization studies at the protein level
have been reported to date.
Epithelial tissues serve as a ®rst line of defense between the host
and the environment. Disturbance of this barrier can lead to the
invasion of microbial pathogens and subsequent in¯ammation.
Previous studies have shown that epithelia that are subjected to
continuous microbial stress or in¯ammatory stimuli (e.g., oral
epithelia, trachea, skin) express several proteins that provide
protection against microbial pathogens and excessive proteolysis
by endogenous and exogenous proteinases. These proteins have
been assigned as a key component of the innate immune system
(Boman, 1998; Lehrer and Ganz, 1999), a system that can be
triggered by infection and protects the host organism against
invading microorganisms (Medzhitov and Janeway, 1998).
Recently, several proteins that are involved in protection against
tissue damage were found to be expressed in human skin in
response to in¯ammatory events. These proteins include two well-
characterized serine proteinase inhibitors with antimicrobial prop-
erties, secretory leukocyte proteinase inhibitor (SLPI) (Hiemstra et
al, 1996; Wiedow et al, 1998; Wingens et al, 1998) and skin-derived
antileukoproteinase (SKALP)/ela®n (Simpson et al, 1999), a
member of the trappin gene family (Zeeuwen et al, 1997;
Schalkwijk et al, 1999). Both proteins are originally described as
inhibitors of polymorphonuclear leukocyte derived enzymes, like
human neutrophil elastase, that are secreted under in¯ammatory
conditions of the skin (e.g., wound healing, psoriasis) (Thompson
and Ohlsson, 1986; Schalkwijk et al, 1990; Wiedow et al, 1990;
Molhuizen et al, 1993; Pfundt et al, 1996).
Much of the barrier function of human epidermis against the
environment is provided by the corni®ed cell envelope (CE)
(Robinson et al, 1997; Nemes and Steinert, 1999), which is
assembled by transglutaminase (TGase) cross-linking of several
structural proteins, like small proline-rich proteins, loricrin,
cytokeratins, ®laggrin, and involucrin (Steinert and Marekov,
1995). Two epidermal proteinase inhibitors were found to be
anchored to structural proteins of the stratum corneum. SKALP/
ela®n was found in foreskin by direct protein sequencing (Steinert
and Marekov, 1997), and cystatin A, the only member of the
cystatin family so far that has been found in human epidermis, was
shown to be part of the CE and acts as a TGase substrate (Takahashi
et al, 1996).
Recently we have started with the construction of a transcrip-
tome of human epidermis using serial analysis of gene expression
(SAGE). Using SAGE we have made an extensive expression
pro®le of cultured human keratinocytes, comprising over 25,000
sequenced tags (Jansen et al, 2001). From this analysis it was clear
that genes involved in host protection and host defense (proteinase
inhibitors and antimicrobial proteins) were expressed at high levels.
Cystatin M/E, not previously known to be expressed by adult
human keratinocytes, was found at considerable levels in these
analyses. In this paper we report the skin-speci®c expression of
cystatin M/E, and its induction by serum in vitro using cultured
human keratinocytes. We demonstrate that cystatin M/E is a
secreted protein and, in addition to its reported antiproteinase
activity, has at least one additional biologic property by acting as an
acyl acceptor in TGase-mediated reactions, thereby becoming a
structural part of the CE.
MATERIALS AND METHODS
Keratinocyte culture Human keratinocytes were obtained from
shave biopsies of adult epidermis (lower back) and were primary cultured
according to the Rheinwald±Green system (Rheinwald and Green,
1975). First passage cells were seeded in keratinocyte growth medium
(KGM; Biowhittaker, Walkersville, MD) as described by van Ruissen et
al (1996). Differentiation of keratinocytes was induced by switching
con¯uent keratinocyte cultures for 72 h to KGM supplemented with 5%
fetal bovine serum (FBS).
Cloning of cystatin M/E in baculovirus Based on the cDNA
sequence of cystatin M/E (Sotiropoulou et al, 1997) we designed two
oligonucleotide primers that could amplify a partial cDNA, encoding
amino acid residue Pro23 to the stop codon at position 150 (cystatin M/
E forward primer, 5¢-GAAGATCTCCACGCGATGCCCG-3¢; cystatin
M/E reverse primer, 5¢-CGGAATTCTCACATCTGCACACAG-3¢),
excluding the amino acid residues corresponding to the hydrophobic
signal peptide (Sotiropoulou et al, 1997). Polymerase chain reactions
(PCR) were carried out using a DNA thermal cycler (PTC-200,
Biozym, Landgraaf, The Netherlands) in 25 ml mixtures. The following
buffer conditions were used: 10 mM Tris-HCl, pH 9.0, 1.5 mM
magnesium chloride, 50 mM potassium chloride, 0.1% Triton X-100, all
four dNTPs (each at 200 mM), 1 unit of Taq DNA Polymerase
(Promega, Madison, WI), and 20 pmol of each primer. After an initial
incubation of 6 min at 94°C ampli®cation was conducted for one cycle
of 1 min at 94°C, 1 min at 47°C, and 2 min at 72°C, followed by 34
cycles with an annealing temperature of 60°C. An additional 10 min at
72°C was used for the last cycle. As template for the PCR we used
cystatin M cDNA (Sotiropoulou et al, 1997). The ampli®ed fragment
was cloned in frame into the pFastbac-HTb baculovirus expression
vector, a component of the Bac-to-Bac Baculovirus Expression System
(Life Technologies). After the recombinant pFastbac-HTb donor plasmid
has been determined to be correct, the DNA is transformed into
competent DH10Bac Escherichia coli cells for transposition into a
baculovirus shuttle vector (bacmid), according to the protocol provided
by the manufacturer. High molecular weight mini-prep DNA is prepared
from selected E.coli clones containing the recombinant bacmid. These
clones were screened for the presence of the desired sequences, and then
used to transfect insect cells.
Production of recombinant baculovirus Recombinant bacmid was
transfected into Spodoptera frugiperda (Sf9) cells using Celfectin Reagent
(Life Technologies) according to the protocol provided by the
manufacturer, followed by infection of insect cells with recombinant
baculovirus particles. The infected cells were harvested and lyzed, the
cell debris was removed by centrifugation, and the supernatant, which
contains the recombinant (His)6-tagged cystatin M/E protein, was stored
at 4°C.
Puri®cation of recombinant cystatin M/E We puri®ed
recombinant cystatin M/E with a Tris-based buffer system according to
the protocol provided by the manufacturer (Bac-to-Bac Baculovirus
Expression System, Life Technologies), with the exception that
2-mercaptoethanol and glycerol were omitted from all buffer solutions.
To obtain recombinant cystatin M/E without the polyhistidine tag, the
baculovirus expressed protein was digested with tobacco etch virus
(TEV) proteinase according to the protocol provided by the
manufacturer (Life Technologies).
Production and puri®cation of recombinant glutathione S-
transferase (GST)±cystatin M/E The recombinant plasmid pGEX-
2T/cystatin M/E was used to produce and purify recombinant GST±
cystatin M/E fusion protein as described previously (Sotiropoulou et al,
1997). To obtain recombinant cystatin M/E without the GST tag, the
bacterially expressed fusion protein was digested with thrombin
according to the protocol provided by the manufacturer (Sigma).
Polyclonal antibodies The puri®ed GST±cystatin M/E fusion
protein was used to immunize a New Zealand White rabbit and a
Duncan Hartley guinea pig, which was carried out at the Central Animal
Laboratory, University of Nijmegen, The Netherlands. Antisera raised
against the GST±cystatin M/E fusion protein were puri®ed by af®nity
chromatography using recombinant fusion protein coupled to CNBr-
activated Sepharose 4B (Pharmacia Biotech).
Autopsic material, skin biopsies, and tape stripping Autopsic
material was obtained from the Department of Pathology, University of
Nijmegen, The Netherlands. The following tissues were studied with
respect to cystatin M/E expression: skin, tongue, gingiva, palatum,
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pharynx, nasal cavity, sole of the foot, esophagus, ileum, colon, stomach,
bronchus, lung, trachea, ureter, kidney, bladder, pancreas, liver, heart,
spleen, skeleton muscle, lymph node, aorta, cartilage, mammary gland,
and uterus. Biopsies of normal skin and from psoriatic lesions were taken
under local anesthesia with a keratome as described by Alkemade et al
(1994).
Immunohistochemistry (IHC) Human skin biopsies and autopsic
material were processed for IHC as previously described (Latijnhouwers
et al, 1996). The sections were subsequently incubated with af®nity-
puri®ed polyclonal rabbit anticystatin M/E antibodies at a 1:50 dilution
followed by IHC staining as described previously (Latijnhouwers et al,
1996).
RNA isolation Total RNA from human cultured keratinocytes and
human tissues was isolated with RNA extraction solution (Wingens et al,
1999). mRNA was isolated using the Quickprep Micro mRNA
Puri®cation Kit (Pharmacia Biotech), according to the manufacturer's
protocol.
Reverse transcriptase PCR (RT-PCR) ampli®cation of the cystatin
M/E transcript First strand cDNA was generated from mRNA as
described previously (Zeeuwen et al, 1997). The reverse transcriptase
reaction products were used for PCR ampli®cation to obtain the cDNA
of cystatin M/E and the housekeeping gene human acidic ribosomal
phosphoprotein P0 (hARP). We designed oligonucleotide primers that
could amplify the cystatin M/E cDNA including the ATG start codon
and the TGA stop codon. These oligonucleotide sequences (®rst sense
then antisense) for the cystatin M/E PCR were 5¢-TCC-
GACGGCACTGACGGC-3¢ and 5¢-CCAATGGCCTTCGCCCTCG-
3¢. The oligonucleotide sequences (®rst sense then antisense) to generate
hARP cDNA were 5¢-ATGTGAAGTCACTGTGCC-3¢ and 5¢-ACC-
AAATCCCATATCCTC-3¢. PCR were carried out using a DNA
thermal cycler (TB1, Biometra, GoÈttingen, Germany) in 25 ml mixtures.
The following buffer conditions were used: 10 mM Tris-HCl, pH 9.0,
1 mM magnesium chloride, 50 mM potassium chloride, 0.1% Triton X-
100, all four dNTPs (each at 200 mM), 1 unit of Taq DNA Polymerase
(Promega), and 20 pmol of each primer. After an initial incubation of
6 min at 94°C ampli®cation was conducted for 35 cycles as follows:
1 min at 94°C, 1 min at annealing temperature, and 2 min at 72°C. An
additional 10 min at 72°C was used for the last cycle. Annealing
temperatures were 58°C when using the cystatin M/E primers and 47°C
for the hARP primers. PCR products were analyzed by agarose gel
electrophoresis.
Northern blot analysis Northern blot analysis was carried out as
described by van Ruissen et al (1996). Cystatin M/E cDNA
(Sotiropoulou et al, 1997) and hARP cDNA were labeled with
(a-32P)dCTP using the Oligolabeling Kit (Pharmacia Biotech) according
to the protocol provided by the manufacturer.
Analysis of cystatin M/E inhibitory activity by enzyme assays
Papain and cathepsin B assay Proteinase inhibitory activity of
recombinant cystatin M/E was determined by measuring the inhibition
of papain (Sigma) and cathepsin B (ICN Pharmaceuticals, Costa Mesa,
CA) essentially described by Abrahamson (1994), using the ¯uorogenic
synthetic substrate Z-Phe-Arg-AMC (Sigma). Papain/cathepsin B was
titrated in the absence and presence of increasing concentrations of
recombinant cystatin M/E.
Cathepsin C assay Extracts of normal human skin were tested for
cathepsin C activity by measuring the hydrolysis of ¯uorogenic substrate
H-Gly-Phe-AMC (Bachum, Bubendorf, Switzerland) using a modi®ed
protocol (Toomes et al, 1999). The amount of ¯uorescence signal
produced from the substrate by skin extract was measured in sodium
phosphate buffer (0.1 M, pH 5.5) containing 100 mM NaCl and 2 mM
dithiothreitol. Substrate hydrolysis was measured after an incubation of
30 min at 37°C. Skin extract (containing cathepsin C) was titrated in the
absence and presence of increasing concentrations of recombinant
cystatin M/E.
Enzyme-linked immunosorbent assay (ELISA) for measurement of
cystatin M/E levels Cystatin M/E concentrations were measured in
supernatant of cultured keratinocytes and human sweat and nasal mucus,
using a sandwich-type ELISA. Microtiter plates (96 ¯at bottom wells)
were coated overnight with puri®ed rabbit anticystatin M/E antiserum
[1:1600 dilution in phosphate-buffered saline (PBS)]. The incubation
steps in this protocol are carried out for 45 min at 37°C, and every
incubation step in the protocol is followed by a washing step with PBS
containing 0.05% Tween-20 (Biorad, Richmond, CA). After washing,
the microtiter plates were blocked with bovine serum albumin (BSA,
10 mg per ml in PBS) with 1% normal goat serum and probed with
dilutions of test samples and standards (recombinant baculovirus
expressed cystatin M/E). As second antibody we used guinea pig
anticystatin M/E antiserum (1:6400 dilution in PBS, 0.05% Tween-20,
0.1% BSA) with 1% normal rabbit serum. Subsequently, the microtiter
plates were incubated with biotinylated goat antiguinea pig IgG (Vector
Laboratories, Burlingame, CA) with 1% normal rabbit serum, followed
by an incubation with the ABC complex. Finally o-phenylenediamine
dihydrochloride (Pierce, Rockford, IL) was added as chromogenic
substrate for 15 min at room temperature. This enzyme reaction was
stopped by the addition of 4 M H2SO4. Data were read with a Biorad
ELISA reader at 492 nm and at 655 nm.
Antimicrobial assays Puri®ed recombinant cystatin M/E
(baculovirus-expressed) without the polyhistidine tag was tested for
antimicrobial activity against the bacterium Staphylococcus aureus 42D and
the yeast Candida albicans UC 820 in an antimicrobial assay as described
previously (Wingens et al, 1998). Recombinant SLPI (a kind gift of Dr.
R.C. Thompson, Synergen, Boulder, CO) and cystatin C (a gift from
the Department of Oral Biochemistry, VU Amsterdam, The
Netherlands) were used in comparison experiments with cystatin M/E.
Preparation of protein extracts Normal skin and epidermal scales
from a psoriatic patient were homogenized in buffer containing 50 mM
Tris-HCl, pH 7.8, and 100 mM sodium chloride. The protein extracts
were centrifuged for 30 min at 25,000 3 g and the supernatant was
subsequently dialyzed against PBS and stored at ±20°C until further use.
Cross-linking of cystatin M/E to stratum corneum proteins by
endogenous TGase For cross-linking experiments 200 mg proteins
from a psoriatic scale extract were used with 2 mg of baculovirus-
expressed puri®ed recombinant cystatin M/E. Buffer and reaction
conditions were as previously described (Zeeuwen et al, 1997). Reaction
mixtures containing 20 mM ethylenediamine tetraacetic acid (EDTA),
pH 7.8, were used as controls. The reaction mixtures were subjected to
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
and electroblotted onto polyvinylidenedi¯uoride (PVDF) membrane
(Millipore, Bedford, MA). The membrane was incubated with af®nity-
puri®ed polyclonal rabbit anticystatin M/E antibodies at a 1:15,000
dilution. This step was followed by incubation with swine antirabbit
horseradish peroxidase (SWARPO; Dako, Glostrup, Denmark) at a
1:1000 dilution. Cross-linked cystatin M/E was detected with the
Phototope-HRP Western Blot Detection Kit (New England Biolabs,
Beverly, MA). This assay uses LumiGLO chemiluminescent reagent and
peroxide. The light emitted by destabilized LumiGLO reagent is
subsequently captured on X-Omat S1 ®lms (Kodak), and processed using
the Imagemaster data image system (Pharmacia).
Cross-linking of biotinylated peptides to cystatin M/E by
exogenous TGase Four hexapeptides, based on the TGase substrate
motif of human SKALP/ela®n (Zeeuwen et al, 1997), with an NH2-
terminal biotin followed by a C6-spacer were synthesized: GQDPVK,
GQDPVR, GNDPVK, and GNDPVR (Eurosequence, Groningen, The
Netherlands). For cross-linking experiments 6 mg of baculovirus-
expressed puri®ed recombinant cystatin M/E was used with 0.5 mg of
biotinylated peptide and 3 ml (0.0313 units per ml) of guinea pig liver
TGase (Sigma). The reaction mixtures were blotted directly onto PVDF
membranes by a slot blot manifold. The membrane was incubated with
an HRP-linked antibiotin antibody, and biotinylated proteins were
detected with the Phototope-HRP Western Blot Detection Kit as
described above.
Puri®cation of cystatin M/E from human skin Af®nity-puri®ed
polyclonal rabbit anticystatin M/E antibody was coupled to CNBr-
activated Sepharose 4B, and this antibody±agarose conjugate was
subsequently used to purify the native cystatin M/E protein from
psoriatic scale extracts according to the protocol provided by the
manufacturer. The collected proteins were subjected to SDS-PAGE and
electroblotted onto PDVF membrane. The membrane was incubated
with af®nity-puri®ed polyclonal rabbit anticystatin M/E and native
cystatin M/E was detected with the Phototope-HRP Western Blot
Detection Kit as described above.
SDS-PAGE and western blotting Samples (TGase assay reaction
mixtures, puri®ed native protein) were diluted with SDS sample buffer
(containing dithiothreitol) and boiled for 2 min. These protein samples
were separated by SDS-PAGE on a 15% Tris-glycine Ready gel (Biorad)
using Tris-glycine as electrophoresis buffer (Laemmli, 1970).
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RESULTS
Cystatin M/E is expressed by epidermal keratinocytes in vitro
and in vivo Keratinocyte gene expression was comprehensively
examined by means of SAGE on cultured human keratinocytes. In
our SAGE library a total of 25,694 tags were analyzed,
corresponding to 10,224 genes, many of which were not known
to be expressed in keratinocytes (for details of this analysis see
Jansen et al, 2001). A large number of keratinocyte-speci®c
transcripts, coding for proteins involved in epidermal
differentiation and skin barrier function, were identi®ed (6% of
all transcripts). Surprisingly, a signi®cant part of the identi®ed
transcripts accounted for genes involved in host protection such as
antimicrobial proteins and proteinase inhibitors (2% of all
transcripts). High expression levels were found for members of
the cystatin family, SLPI and SKALP/ela®n. Cystatin M/E, a
recently described family 2 cystatin not previously known to be
expressed by adult human keratinocytes, was found at intermediate
levels in the SAGE library of cultured keratinocytes (0.04% of all
transcripts). On the basis of its expression in our SAGE library we
decided to investigate whether cystatin M/E was also expressed in
human skin in vivo. Af®nity-puri®ed polyclonal antibodies against
recombinant cystatin M/E were used for a comprehensive
expression study on a large panel of human tissues (see Materials
and Methods for a complete list of tissues examined). We found that
cystatin M/E showed a tissue-speci®c expression pattern that was
limited to epithelial cells in skin and nasal cavity. Figure 1 shows
the immunolocalization of cystatin M/E in these tissues. In normal,
nonpalmoplantar skin, cystatin M/E is highly expressed in the
stratum granulosum and weakly in the spinous layers (Fig 1a).
Positive staining for cystatin M/E in several (®ve to seven) layers of
suprabasal spinous cells was seen in psoriatic lesional skin (Fig 1b),
whereas the granular cells are not stained as strongly as in normal
skin. Differentiated keratinocytes of the infundibular epithelium of
the hair follicle were also found to be positive for cystatin M/E
(Fig 1c). In plantar skin, positive staining for cystatin M/E was seen
in several layers of the suprabasal spinous cells (Fig 1d), which
resembles the pattern in psoriatic skin. In the epidermis of the foot
sole, a duct of a sweat gland is positively stained for cystatin M/E
(Fig 1d, arrowhead). The secretory coils of eccrine sweat glands that
are found in the deep dermal part of the foot sole (Fig 1e) are also
positively stained for cystatin M/E (arrow). In contrast with the
Figure 2. RT-PCR analysis of cystatin M/E expression in human tissues. RT-PCR products derived from mRNA of a large panel of human
tissues were elecrophoretically separated on agarose gel. At the top, ampli®cations performed with cystatin M/E speci®c primers. At the bottom,
ampli®cations performed with hARP speci®c primers, which served as a reference housekeeping gene.
Figure 1. Immunohistology of human skin.
Formalin ®xed sections of biopsies were incubated
with puri®ed rabbit anticystatin M/E polyclonal
antibodies. (A) Normal skin. The staining is
limited to the upper layers of the suprabasal
compartment, which contains mainly granular
cells. (B) Psoriatic lesional skin. Staining of
cystatin M/E is less intense in the stratum
granulosum, but several layers of the suprabasal
spinous cells are positive. No staining was seen in
the basal cells, either in normal skin or psoriatic
lesional skin. (C) Hair follicle. Strong staining of
differentiated keratinocytes of the infundibular
epithelium. (D) Epidermis of the sole of the foot.
A strong staining was observed in several layers of
the differentiated compartment. (E) Sweat glands
in the sole of the foot. Note that the secretory
coil of the gland is strongly positive, whereas the
ductal part is almost negative. (F) Mucous glands
of the nasal cavity show a weak positive staining.
Scale bar: 40 mm.
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epidermal part of the sweat gland duct, the dermal part of the duct
is almost negative (arrowheads). A slight cystatin M/E staining is
found in mucous glands in the nasal cavity (Fig 1f, arrows). No
expression of cystatin M/E was seen in any of the other human
tissues examined by IHC (data not shown). To examine the
expression at the mRNA level we performed RT-PCR analysis on
almost the same panel of human tissues. As shown in Fig 2, this
analysis con®rmed that cystatin M/E gene expression is restricted to
human skin, which is demonstrated by the 496 bp PCR product,
generated using cystatin M/E speci®c oligonucleotides. Sequencing
of this 496 bp product was performed to verify that it was indeed
cystatin M/E. Because the availability of the mRNA of the various
tissue samples was limited, we could not perform northern blot
analysis on all of them, which would give a more quantitative
measure for mRNA levels. Northern blot analysis was performed
on skin biopsies (n = 7), foot sole (n = 1), oral epithelia (n = 1),
and peripheral blood leukocytes (n = 5), which revealed a strongly
hybridizing band of 0.6 kb in the lanes loaded with RNA from skin
(Fig 3, lanes 1±7). A weak signal was seen in foot sole but this lane
was clearly underloaded compared to normal skin (lane 8), whereas
oral epithelia (lanes 9±11) and all blood samples were negative for
cystatin M/E (lanes 12±16).
Isolation and characterization of recombinant cystatin
M/E To further investigate the functional properties of
cystatin M/E we produced recombinant protein, both in a
bacterial expression system as a GST fusion protein and as a fully
processed protein (lacking the signal peptide) in an eukaryotic
system using the baculovirus in insect cells. The puri®ed GST
fusion protein was detected on SDS-PAGE as a single ~40 kDa
band as previously described (Sotiropoulou et al, 1997) (Fig 4, lane
1). Cystatin M/E cleaved from the GST±cystatin M/E fusion
protein by thrombin migrates with an apparent size of ~14 kDa
(Fig 4, lane 2). The puri®ed baculovirus-expressed protein was
found on SDS-PAGE as a doublet of, respectively, ~14 and
~16 kDa, where the upper band was suspected to be a glycosylated
species of cystatin M/E (Ni et al, 1997) (Fig 4, lane 3). To test
whether both recombinant proteins are functional proteinase
inhibitors, cystatin M/E inhibitory activity was measured by
titration of papain activity in the absence and presence of increasing
concentrations of inhibitor, as described by Sotiropoulou et al
(1997). It was found that baculovirus expressed (not shown) and
bacterially expressed cystatin M/E both displayed inhibitory
activity against the cysteine proteinase papain. The inhibitory
activity of cystatin M/E cleaved from the GST±cystatin M/E fusion
protein is shown in Fig 5. Papain hydrolysis of the ¯uorogenic
substrate Z-Phe-Arg-AMC was almost completely inhibited in the
presence of 5 nM cystatin M/E (Fig 5a), whereas recombinant
GST did not have any effect on papain activity (not shown). Using
the same assay we found a moderate inhibitory activity against
cathepsin B as cystatin M/E was used up to micromolar
concentrations (Fig 5b). As de®ciency for cathepsin C was
recently described to be the cause of Papillon±LefeÁvre syndrome
(Hart et al, 1999), cathepsin C is likely to be an important
proteinase for epidermal homeostasis. For this reason we were
interested to know if cystatin M/E could inhibit cathepsin C. Based
on the pH-dependent activation of cathepsin C by chloride ions
(Cigic and Pain, 1999), and using a cathepsin C speci®c synthetic
substrate (H-Gly-Phe-AMC), we could demonstrate the presence
of cathepsin C in normal human skin extracts. No inhibition of
substrate hydrolysis could be detected, however, in the presence of
increasing amounts of recombinant cystatin M/E (Fig 5c). In
addition to its proteinase inhibitory activity, we tested cystatin M/E
for possible direct antimicrobial activity as was described for other
known proteinase inhibitors. Recombinant baculovirus expressed
cystatin M/E, which was digested with TEV proteinase to remove
the polyhistidine tag, showed no detectable bacterial killing against
the tested gram-positive bacterium S. aureus, whereas SLPI, a well-
known broad-range antimicrobial protein, effectively inhibits
growth of this bacterium (data not shown). Additionally, the
growth of C. albicans was completely inhibited by SLPI, whereas
cystatin M/E and cystatin C appeared to be ineffective.
Cystatin M/E is a target for cross-linking by
TGase The expression pattern of cystatin M/E raised the
possibility that this protein could be involved in barrier function
in human skin. Furthermore, its presence in terminally
differentiated keratinocytes as demonstrated with IHC
suggested that it could be a structural part of the stratum
corneum, e.g., by TGase-mediated cross-linking. In earlier work
we reported that the serine proteinase inhibitor SKALP/ela®n
possesses TGase substrate motifs that can act as an anchoring
sequence to corni®ed envelope proteins (Zeeuwen et al, 1997).
To investigate if cystatin M/E is a possible substrate for TGase,
we used biotinylated hexapeptide probes based on the TGase
substrate motif of human SKALP/ela®n in cross-linking
reactions that were catalyzed by exogenous tissue type 2
TGase. The TGase cross-linking reaction is based on a Ca2+-
dependent exchange of primary amines for ammonia at the g-
carboxamide group of glutamine residues. Peptide-bound lysine
residues or polyamines serve as the primary amines to form
either e-(g-glutamyl)lysine or (g-glutamyl)polyamine bonds
between proteins (Folk and Finlayson, 1977), which are
highly resistant to chemical and enzymatic degradation (Folk,
1983). Recombinant cystatin M/E was shown to be an ef®cient
substrate for tissue type 2 TGase (Fig 6a). Cross-linking was
demonstrated using the GQDPVK hexapeptide (an acyl donor
and acceptor probe) and the GQDPVR hexapeptide (an acyl
donor probe). No cross-linking was observed, however, when
the GNDPVK hexapeptide (an acyl acceptor probe) or
GNDPVR hexapeptide (a probe in which both Q and K
have been replaced, and which is no longer a TGase substrate)
were used, indicating that cystatin M/E acts as an acyl acceptor.
Speci®city was checked by the addition of excess EDTA, as a
control for the Ca2+-dependent reaction (not shown). In
addition to cross-linking of cystatin M/E to the biotinylated
hexapeptides, we also used an aqueous extract of stratum
corneum derived from a psoriatic patient as a source of natural
substrate proteins and endogenous TGases (Fig 6b). Analysis by
SDS-PAGE showed incorporation of cystatin M/E in proteins
predominantly between 30 and 100 kDa (lane 4), whereas the
addition of excess EDTA prevents cross-linking of cystatin M/E
(lane 5). Lane 3 is a blank of stratum corneum extract without
cystatin M/E added. To check self cross-linking, recombinant
cystatin M/E was incubated with exogenous TGase type 2
Figure 3. Northern blot analysis of cystatin M/E expression in human tissues. Ten micrograms of total RNA were loaded and probed with
32P-labeled cystatin M/E cDNA. hARP was used for control hybridization to check for equal mRNA loading. Lanes 1, 4, and 7 represent normal skin,
and lanes 2, 3, 5, and 6 represent psoriatic skin. Foot sole (lane 8) and oral epithelia (lanes 9±11), which represent, respectively, tongue, gingiva, and
pharynx, are negative for cystatin M/E expression. Also, several samples of RNA derived from peripheral blood leukocytes were negative for cystatin
M/E (lanes 12±16).
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without the scale extract (lane 2), but no additional bands were
detected.
Induction of cystatin M/E in cultured human
keratinocytes Two other epidermal host defense proteins that
were recently described (SKALP/ela®n and SLPI) are known to be
induced in differentiated cultures of epidermal keratinocytes
(Wingens et al, 1998; Pfundt et al, 2000). We investigated the
induction of cystatin M/E by FBS, as we have previously shown
that SKALP/ela®n and SLPI are both highly upregulated by FBS or
normal human serum (Molhuizen et al, 1995). We used culture
systems that we have previously described (van Ruissen et al, 1996)
that allow the induction of regenerative differentiation of
keratinocytes by the addition of serum. Northern blot analysis
(Fig 7) showed that cystatin M/E mRNA is strongly upregulated
in these cultures. This induction was also found at the protein level
as detected by ELISA on the supernatant of cultured keratinocytes.
In undifferentiated keratinocytes we found no detectable amounts
of cystatin M/E in the supernatant, whereas the supernatant of
differentiated keratinocytes contained signi®cant levels of cystatin
M/E (85 ng per ml).
Cystatin M/E is a secreted protein in vitro and in vivo Based
on the hydrophobic amino acid N-terminal sequence of cystatin
M/E (Sotiropoulou et al, 1997), coding for a putative signal
peptide, it was supposed that cystatin M/E could be secreted. As
mentioned in the previous paragraph, cystatin M/E was found to
be secreted in vitro in the supernatant of cultured keratinocytes. We
also demonstrated by ELISA that cystatin M/E is secreted in vivo in
human sweat and in low amounts in nasal mucus (respectively 88
and 7 ng per ml). These results were con®rmed by western blot
analysis, which showed a single ~14 kDa band of cystatin M/E in
concentrated (53) culture supernatant of differentiated
keratinocytes and concentrated human sweat (Fig 8, lanes 2±3),
whereas in concentrated culture supernatant of undifferentiated
keratinocytes no cystatin M/E could be detected (Fig 8, lane 1).
For comparison, recombinant cystatin M/E cleaved from the fusion
protein was run on the gel (Fig 8, lane 4). We could also detect
native cystatin M/E in psoriatic scale extracts, which was puri®ed
by af®nity chromatography (Fig 8, lane 5).
DISCUSSION
SAGE is an ef®cient and comprehensive approach to examining
cellular gene expression pro®les, as we have recently done on
cultured human keratinocytes (Jansen et al, 2001). Using this
technique we have identi®ed a number of new genes, and several
genes not previously known to be expressed in epidermis. One of
these, cystatin M/E, is characterized in this paper. We show by
IHC that cystatin M/E protein expression in vivo is largely restricted
to human skin. This observation is an apparent discrepancy with
previous studies, which have reported expression of cystatin M/E at
the mRNA level in several other human tissues (Ni et al, 1997;
Sotiropoulou et al, 1997). These two papers, however, are also
contradictory with respect to the observed expression in tissues
such as brain, liver, and peripheral blood leukocytes. A possible
explanation for the inconsistencies between these two papers is a
difference between expression at the mRNA and protein level. We
have found, however, that northern blotting and RT-PCR analysis
on mRNA extracted from fresh autopsy and biopsy material
con®rms the speci®c expression of cystatin M/E in human skin. It
is therefore likely that additional, hitherto unidenti®ed transcripts
Figure 4. Puri®cation of recombinant cystatin M/E. SDS-PAGE in
a 20% gel on the PhastSystem and silver staining. Bacterially expressed
and af®nity puri®ed recombinant GST±cystatin M/E fusion protein, and
cystatin M/E cleaved from the fusion protein by thrombin are shown in
lanes 1 and 2, respectively. Baculovirus expressed and af®nity puri®ed
recombinant cystatin M/E is shown in lane 3. Lane M, molecular weight
markers, with sizes of relevant bands indicated at the left.
Figure 5. Cystatin M/E inhibitory activity. Inhibition of cysteine
proteinases by cystatin M/E was measured by titration of (A) papain, (B)
cathepsin B, and (C) cathepsin C activity in the absence and presence of
increasing concentrations of inhibitor. The ¯uorogenic substrate Z-Phe-
Arg-AMC was used in the papain and cathepsin B enzyme assay,
whereas H-Gly-Phe-AMC was used in the cathepsin C enzyme assay.
Representative curves of at least three experiments are shown.
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with high similarity to the cystatin M/E probe are present in
specialized tissues (Ni et al, 1997). This assumption is plausible
considering that transcripts larger in size than 0.6 kb were found by
northern blot analysis (Sotiropoulou et al, 1997), and it was not
clear whether these transcripts originate from cystatin M/E or from
a closely related gene.
High cystatin M/E expression at the protein level was found
only in the stratum granulosum of normal skin, in hair follicle, and
in eccrine sweat glands. In psoriatic skin an increased number of
cystatin M/E positive cells was found, possibly resulting from
in¯ammatory cytokines that are known to induce abnormal
differentiation (Pfundt et al, 2000). Cysteine proteinases and their
endogenous inhibitors are known to be present in human eccrine
sweat (Yokozeki et al, 1991), and cystatin M/E could be one of the
natural inhibitors. The constitutive expression could be explained
by high levels of cytokines, which are present in normal human
skin eccrine sweat gland duct and secretory coil epithelium (Boehm
et al, 1994). Further regulatory features of cystatin M/E and the
possible involvement of in¯ammatory cytokines remain to be
investigated, however.
Both in vivo and in vitro we found that cystatin M/E is a secreted
protein. Using IHC, however, we could demonstrate high levels
within the cells. In addition, the ®nding that cystatin M/E could be
cross-linked to stratum corneum proteins, a process that occurs
within the cell during terminal differentiation, opens the possibility
that cystatin M/E also acts within the cell. Although these ®ndings
appear paradoxical, similar data have been reported for SKALP/
ela®n and SLPI, two other secreted epidermal proteinase inhibitors.
SKALP/ela®n, which is secreted into the extracellular space, was
found to be cross-linked to loricrin and other corni®ed envelope
components (Steinert and Marekov, 1995), and ultrastructurally it
was found in granules other than secretory lamellar granules (Pfundt
et al, 1996). SLPI, a secreted proteinase inhibitor, is known to
interfere with lipopolysaccharide signaling (Jin et al, 1997), but
rather surprisingly it was recently shown that SLPI acts intracellu-
larly rather than extracellularly (Zhu et al, 1999). By analogy, these
®ndings leave open the possibility that cystatin M/E has multiple
functions, both intracellularly and extracellularly.
The presence of cystatin M/E in the stratum granulosum opens
the possibility that this molecule has a role in the physical barrier of
human skin formed by the stratum corneum. The protective callus
layer resulting from terminal differentiation of the squamous
epithelium is thought to be cross-linked by different TGase
activities present in mammalian epidermis. Four TGases (TGase 1,
2, 3, and X) are known to be expressed in the epidermis
(Greenberg et al, 1991; Kim et al, 1991; 1994; Steinert and
Marekov, 1995; Aeschlimann et al, 1998), but thus far only limited
data are available with respect to their substrate speci®cities and
relative contributions in CE assembly. In vitro, we have shown that
cystatin M/E is an ef®cient substrate for tissue type 2 TGase in
cross-linking reactions with biotinylated hexapeptides. Cross-
linking of the biotinylated GQDPVK and GQDPVR hexapeptides
to recombinant cystatin M/E was observed, but substitution of the
acyl donor residue glutamine (Q) for asparagine (N) totally
abolished cross-linking of the biotinylated GNDPVK and
GNDPVR hexapeptides. From these results we can surmise that
cystatin M/E acts as an acyl acceptor but not as acyl donor. We
could not detect oligomerization of recombinant cystatin M/E in a
reaction with exogenous TGase 2, suggesting that the glutamine
(Q) residues of cystatin M/E do not take part in the cross-linking
reaction catalyzed by TGase 2.
Figure 7. Induction of cystatin M/E mRNA expression in
cultured keratinocytes by FBS. Ten micrograms of total RNA was
loaded and probed with 32P-labeled cystatin M/E cDNA. To check for
equal RNA loading, the 18S and 28S ribosomal RNA signals are shown
in adjacent lanes (lanes 1 and 3). Lane 2, undifferentiated keratinocytes
cultured in basal medium (KGM); lane 4, differentiated keratinocytes
cultured in KGM with FBS.
Figure 8. Detection of cystatin M/E by western blotting.
Concentrated culture supernatants of undifferentiated keratinocytes and
differentiated keratinocytes are shown in lanes 1 and 2, respectively,
whereas concentrated human sweat is shown in lane 3. Lane 4,
recombinant cystatin M/E (14 kDa) cleaved from the fusion protein; lane
5, af®nity puri®ed native cystatin M/E from psoriatic scale extract.
Figure 6. Cystatin M/E is a target for cross-linking by TGase. (A)
Chemiluminescent detection of slot-blotted biotinylated proteins
demonstrating TGase-mediated cross-linking to cystatin M/E.
Baculovirus expressed cystatin M/E incubated with different biotinylated
hexapeptides: GQDPVK, GQDPVR, GNDPVK, and GNDPVR.
Amino acid residues that substitute for acyl acceptor (K) and acyl donor
(Q) residues are underlined. (B) Western blot analysis of SDS-PAGE
demonstrating stratum corneum protein cross-linking to recombinant
cystatin M/E by endogenous TGases: 50 ng cystatin M/E (lane 1), and
50 ng cystatin M/E incubated with exogenous TGase type 2 (lane 2);
stratum corneum protein extract of psoriatic scales (lane 3), incubated
with cystatin M/E (lane 4), and with cystatin M/E in the presence of
EDTA (lane 5). Staining was performed with an af®nity puri®ed
polyclonal rabbit antiserum against recombinant cystatin M/E.
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Desquamation is the ®nal event in terminal differentiation of the
epidermis, which occurs by the action of proteolytic enzymes.
During desquamation there is proteinase-mediated breakdown of
the desmosomal cohesive complexes that link the corneocytes
(Lundstrom and Egelrud, 1990a, b; Suzuki et al, 1994). There is
some evidence indicating that stratum corneum chymotryptic
enzyme (SCCE), a serine proteinase, is responsible for the
degradation of desmosomes leading to desquamation (Egelrud
and Lundstrom, 1991; Hansson et al, 1994). Recently the inhibition
of SCCE by SLPI was described, which may be of importance in
the regulation of epidermal homeostasis (Franzke et al, 1996).
Besides other stratum corneum serine proteinases that have been
implicated in desquamation (Suzuki et al, 1993; Brattsand and
Egelrud, 1999; Ekholm et al, 2000), recently an aspartic proteinase,
cathepsin D, was found that appears to be associated with the ®nal
stage of desquamation (Horikoshi et al, 1999). Lysosomal cysteine
proteinases such as cathepsin B and L are known to be expressed in
the basal and spinous layers of normal skin mainly as inactive
precursors. These proteins were processed to activated mature
enzymes in psoriatic epidermis (Kawada et al, 1997), where they are
thought to be involved in the keratinization process. Cystatin M/E
is a moderately active inhibitor of cathepsin B, which indicates that
this cysteine proteinase inhibitor could have a possible function in
the regulation of keratinization and desquamation. It is more likely,
however, that the target protein for cystatin M/E is found in the
extracellular space as it could be secreted. Interestingly, a new
cysteine proteinase of late epidermal differentiation, stratum
corneum thiol proteinase (SCTP), was recently described by
Watkinson (1999), and could be a possible target enzyme for
cystatin M/E. SCTP appears to be a speci®c product of differen-
tiated keratinocytes, and furthermore it is apparently not stored
within these cells but is actively secreted. A role for SCTP in
degradation of extracellular stratum corneum substrates, which
have been linked with the desquamatory process, and its possible
regulation by cystatin M/E remain to be explored.
Finally, in addition to a role in regulation of endogenous
proteinases, it is conceivable that cystatin M/E is involved in
regulation of exogenous proteinases derived from the commensal
skin ¯ora or potential skin pathogens. Although we could not
demonstrate a direct microbicidal effect in vitro, it is very possible
that microbial proteinases involved in skin colonization and
invasion are targets for cystatin M/E. Clearly, identi®cation of
potential microbial target proteins or generation of cystatin M/E
knockout mice could shed further light on the biologic function of
this molecule and its presumed role in epidermal homeostasis.
We thank Anke van Vught (Department of Ophthalmology, University Hospital
Nijmegen, The Netherlands) for technical assistance on the recombinant baculovirus
procedures, and Ilse Breuker (Department of Medical Microbiology, University
Hospital Nijmegen, The Netherlands) for technical assistance and providing
materials for the antimicrobial assays. This work was ®nancially supported by the
Netherlands Organization for Scienti®c Research (NWO), and in part by the
Dutch Cancer Society (KWF).
REFERENCES
Abrahamson M: Cystatins. Meth Enzymol 244:685±700, 1994
Aeschlimann D, Koeller MK, Allen-Hoffmann BL, Mosher DF: Isolation of a cDNA
encoding a novel member of the transglutaminase gene family from human
keratinocytes. Detection and identi®cation of transglutaminase gene products
based on reverse transcription-polymerase chain reaction with degenerate
primers. J Biol Chem 273:3452±3460, 1998
Alkemade JA, Molhuizen HO, Ponec M, et al: SKALP/ela®n is an inducible
proteinase inhibitor in human epidermal keratinocytes. J Cell Sci 107:2335±
2342, 1994
Bjorck L: Proteinase inhibition, immunoglobulin-binding proteins and a novel
antimicrobial principle. Mol Microbiol 4:1439±1442, 1990
Bjorck L, Akesson P, Bohus M, Trojnar J, Abrahamson M, Olafsson I, Grubb A:
Bacterial growth blocked by a synthetic peptide based on the structure of a
human proteinase inhibitor. Nature 337:385±386, 1989
Bjorck L, Grubb A, Kjellen L: Cystatin C, a human proteinase inhibitor, blocks
replication of herpes simplex virus. J Virol 64:941±943, 1990
Blankenvoorde MF, van't Hof W, Walgreen-Weterings E, van Steenbergen TJ,
Brand HS, Veerman EC, Nieuw Amerongen AV: Cystatin and cystatin-
derived peptides have antibacterial activity against the pathogen Porphyromonas
gingivalis. Biol Chem 379:1371±1375, 1998
Bobek LA, Levine MJ: Cystatins ± inhibitors of cysteine proteinases. Crit Rev Oral
Biol Med 3:307±332, 1992
Boehm KD, Yun JK, Garner C, Strohl KP, Elmets CA: In situ detection of cytokine
messenger RNAs in the eccrine sweat gland of normal human skin. Lymphokine
Cytokine Res 13:9±13, 1994
Boman HG: Gene-encoded peptide antibiotics and the concept of innate immunity:
an update review. Scand J Immunol 48:15±25, 1998
Brattsand M, Egelrud T: Puri®cation molecular cloning, and expression of a human
stratum corneum trypsin-like serine protease with possible function in
desquamation. J Biol Chem 274:30033±30040, 1999
Calkins CC, Sloane BF: Mammalian cysteine protease inhibitors: biochemical
properties and possible roles in tumor progression. Biol Chem Hoppe Seyler
376:71±80, 1995
Cigic B, Pain RH: Location of the binding site for chloride ion activation of
cathepsin C. Eur J Biochem 264:944±951, 1999
Egelrud T, Lundstrom A: A chymotrypsin-like proteinase that may be involved in
desquamation in plantar stratum corneum. Arch Dermatol Res 283:108±112,
1991
Ekholm IE, Brattsand M, Egelrud T: Stratum corneum tryptic enzyme in normal
epidermis: a missing link in the desquamation process? J Invest Dermatol 114:56±
63, 2000
Folk JE: Mechanism and basis for speci®city of transglutaminase-catalyzed epsilon-
(gamma-glutamyl) lysine bond formation. Adv Enzymol Relat Areas Mol Biol
54:1±56, 1983
Folk JE, Finlayson JS: The epsilon-(gamma-glutamyl) lysine crosslink and the
catalytic role of transglutaminases. Adv Protein Chem 31:1±133, 1977
Franzke CW, Baici A, Bartels J, Christophers E, Wiedow O: Antileukoprotease
inhibits stratum corneum chymotryptic enzyme. Evidence for a regulative
function in desquamation. J Biol Chem 271:21886±21890, 1996
Greenberg CS, Birckbichler PJ, Rice RH: Transglutaminases multifunctional cross-
linking enzymes that stabilize tissues. FASEB J 5:3071±3077, 1991
Hansson L, Stromqvist M, Backman A, Wallbrandt P, Carlstein A, Egelrud T:
Cloning expression, and characterization of stratum corneum chymotryptic
enzyme. A skin-speci®c human serine proteinase. J Biol Chem 269:19420±
19426, 1994
Hart TC, Hart PS, Bowden DW, et al: Mutations of the cathepsin C gene are
responsible for Papillon±LefeÁvre syndrome. J Med Genet 36:881±887, 1999
Henskens YM, Veerman EC, Nieuw Amerongen AV: Cystatins in health and
disease. Biol Chem Hoppe Seyler 377:71±86, 1996
Hiemstra PS, Maassen RJ, Stolk J, Heinzel-Wieland R, Steffens GJ, Dijkman JH:
Antibacterial activity of antileukoprotease. Infect Immun 64:4520±4524, 1996
Horikoshi T, Igarashi S, Uchiwa H, Brysk H, Brysk MM: Role of endogenous
cathepsin D-like and chymotrypsin-like proteolysis in human epidermal
desquamation. Br J Dermatol 141:453±459, 1999
Jansen BJ, van Ruissen F, de Jongh GJ, Zeeuwen PL, Schalkwijk J: Serial analysis of
gene expression (SAGE) in human epidermal keratinocytes reveals high
expression levels of genes involved in host defense and protection. J Invest
Dermatol 116:12±22, 2001
Jin FY, Nathan C, Radzioch D, Ding A: Secretory leukocyte protease inhibitor: a
macrophage product induced by and antagonistic to bacterial
lipopolysaccharide. Cell 88:417±426, 1997
Kawada A, Hara K, Kominami E, Hiruma M, Noguchi H, Ishibashi A: Processing of
cathepsins L, B, D in psoriatic epidermis. Arch Dermatol Res 289:87±93, 1997
Kim HC, Idler WW, Kim IG, Han JH, Chung SI, Steinert PM: The complete amino
acid sequence of the human transglutaminase K enzyme deduced from the
nucleic acid sequences of cDNA clones. J Biol Chem 266:536±539, 1991
Kim IG, Lee SC, Lee JH, Yang JM, Chung SI, Steinert PM: Structure and
organization of the human transglutaminase 3 gene: evolutionary relationship
to the transglutaminase family. J Invest Dermatol 103:137±142, 1994
Korant BD, Towatari T, Ivanoff L, Petteway S, Brzin J, Lenarcic B, Turk V: Viral
therapy: prospects for protease inhibitors. J Cell Biochem 32:91±95, 1986
Laemmli UK: Cleavage of structural proteins during the assembly of the head of
bacteriophage T4. Nature 227:680±685, 1970
Latijnhouwers MA, Bergers M, van Bergen BH, Spruijt KI, Andriessen MP,
Schalkwijk J: Tenascin expression during wound healing in human skin. J
Pathol 178:30±35, 1996
Lehrer RI, Ganz T: Antimicrobial peptides in mammalian and insect host defence.
Curr Opin Immunol 11:23±27, 1999
Lundstrom A, Egelrud T: Evidence that cell shedding from plantar stratum corneum
in vitro involves endogenous proteolysis of the desmosomal protein desmoglein
I. J Invest Dermatol 94:216±220, 1990a
Lundstrom A, Egelrud T: Cell shedding from human plantar skin in vitro: evidence
that two different types of protein structures are degraded by a chymotrypsin-
like enzyme. Arch Dermatol Res 282:234±237, 1990b
Medzhitov R, Janeway CA: Innate immune recognition and control of adaptive
immune responses. Semin Immunol 10:351±353, 1998
Molhuizen HO, Alkemade HA, Zeeuwen PL, de Jongh GJ, Wieringa B, Schalkwijk
J: SKALP/ela®n: an elastase inhibitor from cultured human keratinocytes.
Puri®cation, cDNA sequence, and evidence for transglutaminase cross-linking.
J Biol Chem 268:12028±12032, 1993
Molhuizen HO, Zeeuwen PL, Pfundt R, Schalkwijk J: Characterization of the
700 ZEEUWEN ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
promotor region of the human skin. In: Molecular and cell biological
characterization of the serine proteinase inhibitor SKALP. Thesis, Katholieke
Universiteit Nijmegen, The Netherlands, 1995:pp 95±116
Nemes Z, Steinert PM: Bricks and mortar of the epidermal barrier. Exp Mol Med
31:5±19, 1999
Ni J, Abrahamson M, Zhang M, et al: Cystatin E is a novel human cysteine proteinase
inhibitor with structural resemblance to family 2 cystatins. J Biol Chem
272:10853±10858, 1997
Pfundt R, van Ruissen F, Vlijmen-Willems IM, et al: Constitutive and inducible
expression of SKALP/ela®n provides anti-elastase defense in human epithelia. J
Clin Invest 98:1389±1399, 1996
Pfundt R, Wingens M, Bergers M, Zweers M, Frenken J, Schalkwijk J: TNF-alpha
and serum induce SKALP/ela®n gene expression in human keratinocytes by a
p38MAP kinase dependent pathway. Arch Dermatol Res 292:180±187, 2000
Rawlings ND, Barrett AJ: Evolution of proteins of the cystatin superfamily. J Mol
Evol 30:60±71, 1990
Rheinwald JG, Green H: Formation of a keratinizing epithelium in culture by a
cloned cell line derived from a teratoma. Cell 6:317±330, 1975
Robinson NA, Lapic S, Welter JF, Eckert RL: S100A11, S100A10, annexin I,
desmosomal proteins, small proline-rich proteins, plasminogen activator
inhibitor-2, and involucrin are components of the corni®ed envelope of
cultured human epidermal keratinocytes. J Biol Chem 272:12035±12046, 1997
van Ruissen F, de Jongh GJ, Zeeuwen PL, van Erp PE, Madsen P, Schalkwijk J:
Induction of normal and psoriatic phenotypes in submerged keratinocyte
cultures. J Cell Physiol 168:442±452, 1996
Schalkwijk J, Chang A, Janssen P, de Jongh GJ, Mier PD: Skin-derived
antileucoproteases (SKALPs): characterization of two new elastase inhibitors
from psoriatic epidermis. Br J Dermatol 122:631±641, 1990
Schalkwijk J, Wiedow O, Hirose S: The trappin gene family: proteins de®ned by an
N-terminal transglutaminase substrate domain and a C-terminal four-
disulphide core. Biochem J 340:569±577, 1999
Simpson AJ, Maxwell AI, Govan JR, Haslett C, Sallenave JM: Ela®n (elastase-speci®c
inhibitor) has anti-microbial activity against gram-positive and gram-negative
respiratory pathogens. FEBS Lett 452:309±313, 1999
Sotiropoulou G, Anisowicz A, Sager R: Identi®cation cloning, and characterization
of cystatin M, a novel cysteine proteinase inhibitor, down-regulated in breast
cancer. J Biol Chem 272:903±910, 1997
Steinert PM, Marekov LN: The proteins ela®n, ®laggrin, keratin intermediate
®laments, loricrin, and small proline-rich proteins 1 and 2 are isodipeptide
cross-linked components of the human epidermal corni®ed cell envelope. J Biol
Chem 270:17702±17711, 1995
Steinert PM, Marekov LN: Direct evidence that involucrin is a major early isopeptide
cross- linked component of the keratinocyte corni®ed cell envelope. J Biol
Chem 272:2021±2030, 1997
Suzuki Y, Nomura J, Hori J, Koyama J, Takahashi M, Horii I: Detection and
characterization of endogenous protease associated with desquamation of
stratum corneum. Arch Dermatol Res 285:372±377, 1993
Suzuki Y, Nomura J, Koyama J, Horii I: The role of proteases in stratum corneum:
involvement in stratum corneum desquamation. Arch Dermatol Res 286:
249±253, 1994
Takahashi M, Tezuka T, Katunuma N: Filaggrin linker segment peptide and cystatin
alpha are parts of a complex of the corni®ed envelope of epidermis. Arch
Biochem Biophys 329:123±126, 1996
Thompson RC, Ohlsson K: Isolation properties, and complete amino acid sequence
of human secretory leukocyte protease inhibitor, a potent inhibitor of
leukocyte elastase. Proc Natl Acad Sci USA 83:6692±6696, 1986
Toomes C, James J, Wood AJ, et al: Loss-of-function mutations in the cathepsin C
gene result in periodontal disease and palmoplantar keratosis. Nat Genet
23:421±424, 1999
Turk V, Bode W: The cystatins: protein inhibitors of cysteine proteinases. FEBS Lett
285:213±219, 1991
Watkinson A: Stratum corneum thiol protease (SCTP): a novel cysteine protease of
late epidermal differentiation. Arch Dermatol Res 291:260±268, 1999
Wiedow O, Schroder JM, Gregory H, Young JA, Christophers E: Ela®n an elastase-
speci®c inhibitor of human skin. Puri®cation, characterization, and complete
amino acid sequence. J Biol Chem 265:14791±14795, 1990
Wiedow O, Harder J, Bartels J, Streit V, Christophers E: Antileukoprotease in
human skin: an antibiotic peptide constitutively produced by keratinocytes.
Biochem Biophys Res Commun 248:904±909, 1998
Wingens M, van Bergen BH, Hiemstra PS, et al: Induction of SLPI (ALP/HUSI-I) in
epidermal keratinocytes. J Invest Dermatol 111:996±1002, 1998
Wingens M, Pfundt R, Vlijmen-Willems IM, van Hooijdonk CA, van Erp PE,
Schalkwijk J: Sequence-speci®c inhibition of gene expression in intact human
skin by epicutaneous application of chimeric antisense oligodeoxynucleotides.
Lab Invest 79:1415±1424, 1999
Yokozeki H, Hibino T, Takemura T, Sato K: Cysteine proteinase inhibitor in
eccrine sweat is derived from sweat gland. Am J Physiol 260:R314±R320, 1991
Zeeuwen PL, Hendriks W, de Jong WW, Schalkwijk J: Identi®cation and sequence
analysis of two new members of the SKALP/ela®n and SPAI-2 gene family.
Biochemical properties of the transglutaminase substrate motif and suggestions
for a new nomenclature. J Biol Chem 272:20471±20478, 1997
Zhu J, Nathan C, Ding A: Suppression of macrophage responses to bacterial
lipopolysaccharide by a non-secretory form of secretory leukocyte protease
inhibitor. Biochim Biophys Acta 1451:219±223, 1999
VOL. 116, NO. 5 MAY 2001 A CYSTEINE PROTEINASE INHIBITOR SPECIFIC FOR HUMAN SKIN 701
